Ilypsa raises $36M to develop polymeric drugs

In a private stock placement, Ilypsa generated $36 million from venture investors, including US Venture Partners, Johnson & Johnson Development, and Delphi Ventures. Ilypsa will use the funds to complete preclinical and initiate clinical development of two compounds aimed at chronic kidney disease and metabolic disorders.

- read this press release for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.